NASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis $9.00 -0.15 (-1.64%) (As of 11:03 AM ET) Add Compare Share Share Today's Range$8.67▼$9.8550-Day Range$7.70▼$15.9052-Week Range$6.69▼$43.00Volume102,756 shsAverage Volume69,017 shsMarket Capitalization$397.53 millionP/E RatioN/ADividend YieldN/APrice Target$34.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get enGene alerts: Email Address enGene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside278.0% Upside$34.40 Price TargetShort InterestHealthy0.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$786,481 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.33) to ($1.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.58 out of 5 starsMedical Sector408th out of 879 stocksHolding & Other Investment Offices Industry1st out of 12 stocks 3.5 Analyst's Opinion Consensus RatingenGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageenGene has only been the subject of 2 research reports in the past 90 days.Read more about enGene's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.14% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in enGene has recently increased by 29.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENGN. Previous Next 2.8 News and Social Media Coverage News SentimentenGene has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for enGene this week, compared to 22 articles on an average week.Search Interest4 people have searched for ENGN on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, enGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $786,481.00 in company stock.Percentage Held by Insiders13.70% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about enGene's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for enGene are expected to decrease in the coming year, from ($1.33) to ($1.51) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About enGene Stock (NASDAQ:ENGN)enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Read More ENGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENGN Stock News HeadlinesJune 14, 2024 | businesswire.comenGene Reports Second Quarter 2024 Financial Results and Provides a Business UpdateMay 29, 2024 | msn.comThe U.S. Air Force's 'New' B-52J Bomber Has Rolls-Royce EnginesJuly 8, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.May 29, 2024 | msn.comToyota, Mazda, and Subaru Collaborating on Next-Gen EnginesMay 29, 2024 | msn.comAre Turbocharged Engines More Or Less Reliable Than Regular Engines?May 29, 2024 | businesswire.comenGene to Present at the Jefferies Global Healthcare ConferenceMay 28, 2024 | msn.comToyota, Mazda and Subaru aren’t ready to give up on “real” engines any time soonMay 28, 2024 | msn.comToyota shows ‘an engine reborn’ with green fuel despite global push for battery electric carsJuly 8, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.May 28, 2024 | ft.comToyota bets on new line of combustion engines in challenge to TeslaMay 28, 2024 | yahoo.comToyota, Mazda and Subaru team up to develop carbon-neutral enginesMay 28, 2024 | msn.comUnited flight aborts takeoff at Chicago’s O’Hare airport after reported engine fire, prompting officials to delay arrivalsMay 28, 2024 | news.yahoo.comUnited Aircraft Engine Catches Fire Just Before Takeoff at Chicago O'HareMay 28, 2024 | msn.comShocking moment plane engine catches fire before takeoff at Chicago airportMay 28, 2024 | bbc.comMuseum donates fire engine to brigade in CroatiaMay 28, 2024 | msn.comUnited Airlines Flight Aborts Takeoff After Engine Catches FireMay 27, 2024 | msn.comSingle-engine plane crashes in Wicomico County fieldMay 27, 2024 | msn.com3 Of The Most Common Problems Drivers Report With The 3.0 Duramax Diesel EngineSee More Headlines Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/14/2024Today7/07/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CUSIPN/A CIK1980845 Webwww.engene.com Phone302-273-0765FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$34.40 High Stock Price Target$40.00 Low Stock Price Target$30.00 Potential Upside/Downside+276.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.66) per share Price / Book-13.86Miscellaneous Outstanding Shares44,170,000Free Float38,115,000Market Cap$404.16 million OptionableN/A Beta-0.63 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Jason D. Hanson Esq. (Age 55)J.D., CEO & Director Comp: $656.58kDr. Alex Nichols Ph.D. (Age 38)President & COO Comp: $504.44kDr. James C. Sullivan M.Sc. (Age 45)Ph.D., Chief Scientific Officer Comp: $524.29kDr. Anthony T. Cheung Ph.D. (Age 52)Co-Founder & CTO Comp: $341.75kMr. John C. Brown D.Sc.FRSC, Ph.D., Co-Founder and Member of Scientific Advisory BoardMr. David Ryan Daws (Age 50)CFO & Head of Business Development Mr. Lee G. Giguere (Age 43)Chief Legal Officer & Corporate Secretary Ms. Sharon TanVP of Project Management & Head of Program ManagementDr. Richard P. Bryce MBChB (Age 67)MFPM, MRCGP, Chief Medical Officer Dr. Raj Pruthi M.D.Senior VP of Urologic Oncology & Clinical DevelopmentMore ExecutivesKey CompetitorsKayne Anderson BDCNYSE:KBDCBain Capital Specialty FinanceNYSE:BCSFChurchill Capital Corp VIINYSE:CVIITrinity CapitalNASDAQ:TRINAres Acquisition Co. IINYSE:AACTView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 1,000,000 shares on 5/16/2024Ownership: 2.295%Altitude Crest Partners Inc.Bought 120,289 shares on 5/15/2024Ownership: 0.276%De Solidarite Des Travai FondsSold 47,854 sharesTotal: $717,810.00 ($15.00/share)De Solidarite Des Travai FondsSold 4,575 sharesTotal: $68,670.75 ($15.01/share)View All Insider TransactionsView All Institutional Transactions ENGN Stock Analysis - Frequently Asked Questions How have ENGN shares performed this year? enGene's stock was trading at $9.23 on January 1st, 2024. Since then, ENGN stock has decreased by 1.4% and is now trading at $9.10. View the best growth stocks for 2024 here. How were enGene's earnings last quarter? enGene Holdings Inc. (NASDAQ:ENGN) posted its quarterly earnings results on Friday, June, 14th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.14. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENGN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
